Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis

Arthritis and Rheumatism

Volumn 43, Issue 2, 2000, Pages 281-288

  Manicourt, Daniel Henri ^a,d   Poilvache, Pascal ^a   Van Egeren, Anne ^a   Devogelaer, Jean Pierre ^b   Lenz, Mary Ellen ^c   Thonar, Eugene J M A ^c  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c RUSH MEDICAL COLLEGE   (United States)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; COLLAGEN; INTERLEUKIN 6; KERATAN SULFATE; ONCOSTATIN M; PYRIDINOLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARTILAGE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; KNEE DISEASE; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL;

ADULT; AGED; AGGRECANS; ANTIGENS; ARTHRITIS, RHEUMATOID; BIODEGRADATION, ENVIRONMENTAL; BIOLOGICAL MARKERS; CARTILAGE; COLLAGEN; CROSS-LINKING REAGENTS; CYTOKINES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GROWTH INHIBITORS; HUMANS; KERATAN SULFATE; LECTINS, C-TYPE; MALE; MIDDLE AGED; ONCOSTATIN M; OSTEOARTHRITIS; PEPTIDES; PROTEOGLYCANS; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034040139     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200002)43:2<281::AID-ANR7>3.0.CO;2-7     Document Type: Article

References (42)

1. Eyre DR, Wu JJ, Woods P. Cartilage-specific collagens: structural studies. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC, editors. Articular cartilage biochemistry. New York: Raven Press; 1992. p. 119-32.
2. Eyre DR. The specificity of collagen crosslinks as markers of bone and connective tissue degradation. Acta Orthop Scand 1995;66 Suppl 266:166-70.
3. Seibel MJ, Duncan A, Robins SP. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic disease. J Rheumatol 1989;16:964-70
4. Lohmander S. Proteoglycans of joint cartilage: structure, function turnover and role as markers of joint disease. Baillieres Clin Rheumatol 1988;2:37-62.
5. Hardingham TE, Fosang AJ, Dudhia J. Aggrecan, the chondroitin sulfate/keratan sulfate from cartilage. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC, editors. Articular cartilage biochemistry. New York: Raven Press; 1992. p. 5-20.
6. Witter J, Roughley PJ, Webber C, Roberts N, Keystone E, Poole AR. The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum 1987;30:519-29.
7. Lohmander LS, Dahlberg L, Ryd L, Heinegärd D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 1989;32:1434-42.
8. Thonar EJ-MA, Lenz ME, Masuda K, Manicourt D-H. Body fluid markers of cartilage metabolism. In: Seibel MJ, Robins SP, Bilezikian JP, editors. Dynamics of bone and cartilage metabolism. San Diego: Academic Press; 1999. p. 453-64.
9. Walport MJ, Duff GW. Cells and mediators of inflammation. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1993. p. 285-96.
10. Poole AR, Alini M, Hollander AP. Cellular biology of cartilage degradation. In: Henderson B. Edwards JCW, Pettipher ER, editors. Mechanisms and models in rheumatoid arthritis. London: Academic Press; 1995. p. 163-204.
11. Skerry T, Gowen M. Bone cells and bone remodeling in rheumatoid arthritis. In: Henderson B, Edwards JCW, Pettipher ER, editors. Mechanisms and models in rheumatoid arthritis. London: Academic Press; 1995. p. 205-20.
12. Houssiau FA, Devogelaer J-P, van Damme J, Nagant de Deuxchaisnes C, van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
13. Manicourt D-H, Triki R, Fukuda K, Devogelaer J-P, Nagant de Deuxchaisnes C, Thonar EJ-MA. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis: relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993;36:490-9.
14. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-78.
15. Rodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993;53 Suppl 1:S94-8.
16. Rose TM, Bruce AG. Oncostatin M is a member of a cytokine family that includes leukemia inhibitory factor, granulocyte stimulating factor and interleukin-6. Proc Natl Acad Sci U S A 1991;88:8641-5.
17. Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin-6-related cytokine subfamily. Stem Cells 1994;12:262-77.
18. Hui W, Bell M, Carroll G. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:184-7.
19. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997;40:1096-105.
20. Hui W, Bell M, Carroll G. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycans in porcine articular cartilage explants. Cytokine 1996;8:495-500.
21. Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. lnterleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun 1995;215:377-85.
22. Myers SL, Brandt KD, Eilam O. Even low-grade synovitis significantly accelerates the clearance of protein from the canine knee: implications for measurement of synovial fluid "markers" of osteoarthritis. Arthritis Rheum 1995;38:1085-91.
23. 99mtechnetium labeled nonspecific human immunoglobulin. J Rheumatol 1995;22:850-4.
24. Jamar F, Leners N, Beckers C, Manicourt D-H. 99m Tc-labelled immunoglobulin scintigraphy in arthritis: an analysis of synovial fluid activity. Scand J Clin Lab Invest 1997;57:621-8.
25. De Bois MH, Tak PP, Arndt JW, Kluim PM, Pauwels EK, Breedveld FC. Joint scintigraphy for quantification of synovitis with 99mTc-labelled human immunoglobulin G compared to histological examination. Clin Exp Rheumatol 1995;13:155-9.
26. De Bois MH, Arndt JW, Tak PP, Kluim PM, van der Velde EA, Pauwels EK, et al. 99 Tcm-labelled polyclonal human immunoglobulin G scintigraphy before and after knee injection of triamcinolone hexacetonide in patients with rheumatoid arthritis. Nucl Med Commun 1993;14:883-7.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. Thonar EJ-MA, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985;28: 1367-76.
29. Ricard-Blum S, Chevalier X, Grimaud JA, Larget-Piet B, Uebelhart D. Detectable levels of pyridinoline are present in synovial fluid from various patients with knee effusion: preliminary results. Eur J Clin Invest 1995;25:438-41.
30. Muller A, Hein G, Franke S, Herrmann D, Henzgen S, Roth A, et al. Quantitative analysis of pyridinium crosslinks of collagen in the synovial fluid of patients with rheumatoid arthritis using high performance liquid chromatography. Rheumatol Int 1996;16:23-8.
31. Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990;49:676-81.
32. Isomäki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996;39:386-95.
33. Balsa UJ, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martin-Mola E, Fontan G. Soluble interleukin-6 (IL-6) receptors and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069-75.
34. Tyler JA, Bolis S, Dingle JT, Middleton JFS. Mediators of matrix catabolism. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC, editors. Articular cartilage biochemistry. New York: Raven Press; 1992. p. 251-64.
35. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998;41:1760-71.
36. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
37. Carroll G, Bell M, Wang H, Chapman H, Mills J. Antagonism of the IL-6 cytokine subfamily - a potential strategy for more effective therapy in rheumatoid arthritis. Inflamm Res 1998;47:1-7.
38. Cawston TE, Ellis AJ, Bigg H, Curry V, Lean E, Ward D. Interleukin-4 blocks the release of collagen fragments from bovine nasal cartilage treated with cytokines. Biochim Biophys Acta 1996;314:226-32.
39. Carroll G, Bell M, Hui W. Role of oncostatin M in the regulation of cartilage macromolecule metabolism: comment on the article by Nemoto et al [letter]. Arthritis Rheum 1997;40:589-90.
40. Gatsios P, Haubeck H-D, van de Leur E, Frisch W, Apte SS, Greiling H, et al. Oncostatin M differentially regulates tissue inhibitors of metalloproteinases TIMP-1 and TIMP-3 gene expression in human synovial lining cells. Eur J Biochem 1996;241:56-63.
41. Nemoto O, Yamada H, Mukaida M, Shimmei M. Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum 1996;39:560-6.
42. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.